*Press release, 18th of October, 2017*

**Introducing OnDosis, a new life science company**

**Based on innovative technology developed by AstraZeneca, OnDosis is a new, Gothenburg-based, life science company with the mission to simplify dosing and enable personalised administration of medicines by connecting medicines, devices and digital health to benefit patients. AstraZeneca and GU Ventures have founded OnDosis together with entrepreneurial CEO, Martin Olovsson.**

Tablets and capsules are currently the most common way to administer oral medicines, but there are numerous limitations with these conventional formulations. Moreover, increased knowledge of personalised medicine has demonstrated a significant unmet need for personalised administration.[[1]](#footnote-1)

To address the rapidly evolving needs of patients and healthcare professionals, OnDosis is developing an intelligent drug delivery platform centered on a handheld dosing device that delivers tailored doses of oral medicines. The device can connect to a wider range of digital health technologies, such as remote dose control and adherence monitoring, opening up numerous opportunities to improve treatment outcomes.

* *“Challenges for a wide range of patients to swallow their medicines, dose titration, non-adherence and potential risk of abuse are just some of the current issues we want to address through OnDosis. The platform brings together flexible and tailored dosing and digital health technologies in an exciting combination that has the potential to create a treatment paradigm shift across multiple disease areas,” says CEO* ***Martin Olovsson****, an entrepreneur with wide-ranging industry experience, who will lead the new company.*

The innovation behind OnDosis has been developed over a number of years in AstraZeneca’s Pharmaceutical technology and development labs. The new company is formed as part of AstraZeneca’s Spin Out project, in which AstraZeneca has collaborated with Vinnova and the Swedish Government to establish a model to build new companies based on innovative ideas developed by established companies. GU Ventures, the incubator and seed investor that is wholly owned by the Swedish State, will build and fund the new company going forward. OnDosis will establish its offices at AstraZeneca’s BioVentureHub in Gothenburg, Sweden.

* *“It’s very exciting to see that this innovative technology has a great opportunity to be developed to its full potential. All parties involved have demonstrated a truly entrepreneurial mindset and we are very proud to contribute, through the founding of OnDosis, to further strengthen the life science industry in Sweden,”**says* ***Magnus Björsne****, CEO for AstraZeneca’s BioVentureHub and a driving force behind the Spin Out project.*

Through partnering and working together, the parties acknowledge OnDosis to be an excellent example of how to collaborate to form start-up companies that will help shape the future of life science industry. The idea behind OnDosis has also been supported by students in the Entrepreneurship in Life Sciences program at Sahlgrenska Academy within the University of Gothenburg and by GU Project Accelerator AB, a subsidiary of GU Ventures.

* *“By integrating personalized medicine and digital health, the potential of the OnDosis technology is obvious. We are enthusiastic about introducing OnDosis after an intensive development period together with all involved parties, and to support the development of the company in our incubator. We appreciate working together with Martin and the AstraZeneca team to start OnDosis and we look forward building an exciting company on the international market,” says* ***Klementina Österberg****, CEO of GU Ventures.*

= = =

**For more information, please contact:**

Martin Olovsson, CEO of OnDosis AB, m.olovsson@ondosis.com, +46 767 728501

Magnus Björsne, CEO of AstraZeneca BioVentureHub, magnus.bjorsne@astrazeneca.com, +46 31 7762858

Klementina Österberg, CEO of GU Ventures, klementina@ventures.gu.se, +46 70 4401190

= = =

**

*Above, from left: Jan Pilebjer, business developer GU Ventures, and Martin Olovsson, CEO OnDosis. Below, from left: Magnus Björsne, CEO AstraZeneca BioVentureHub, and Klementina Österberg, CEO GU Ventures.*

= = =

**About OnDosis**

OnDosis is developing a smart drug delivery platform for personalized and connected dosing of medicines. OnDosis builds on a spin out from AstraZeneca with offices in their BioVentureHub in Gothenburg. The OnDosis devices combine tailored and flexible dosing and mobile health technologies with the objective to improve treatment outcomes for a wide array of diseases and patients. The first OnDosis product is under development with the aim to reach the market in 2020. Please visit: [www.ondosis.com](http://www.ondosis.com)

**About AstraZeneca BioVentureHub**

AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private-partnership model and located at the heart of AstraZeneca Gothenburg, the BioVentureHub gives emerging biotech/medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with - and tap into - the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other. Please visit: [azbioventurehub.com](http://www.azbioventurehub.com/)

**About GU Ventures**

GU Ventures AB is fully owned by the Swedish government and is managed since 1998 by the University of Gothenburg. The mission is to commercialise ideas in connection to the operations at the University of Gothenburg and to deliver economic and social benefits. To ensure this, GU Ventures builds and invests its own funds in new businesses, which are actively supported in the GU Ventures incubator that provides business development and administrative support. With over 140 new businesses established, that have lead to 30 exits and 11 IPOs already for GU Ventures, UBI Global Index has top ranked GU Ventures for its incubation and investment operations. Please visit: [www.guventures.com](http://www.guventures.com)

1. *Source: Wening and Breitkreutz, Int J Pharm, 2011* [↑](#footnote-ref-1)